A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Summary

This is a phase 1 clinical trial designed to evaluate increasing durations of MLN8054 oral dosing in patients with advanced malignancies. MLN8054 will be given once daily for 4 to 7 consecutive days per week for 2 to 3 weeks. Following the 2- to 3-week treatment period there will be a 2 week recovery period.

Timeline

Start

2006-04

Primary completion

2008-03

Completion

2008-04

Drugs

Indications